UNSPSC 51282328: Erythromycin succinate

This classification denotes a macrolide antibiotic with the molecular formula C41H71NO16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 831SF5M65L. Most nations, for tariff and trade purposes, schedule erythromycin succinate under HS 29415000 and SITC 54139. As of Q4 2014, ERYTHROMYCIN SUCCINATE remains US FDA's Preferred Term for this commodity.

SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CCC(=O)O)(C)O)C)C)O)(C)O.

UNSPSC 51282328 Erythromycin succinate is a Commodity code for a specific antibiotic pharmaceutical product, but the recent state and local opportunities tagged under it show minimal activity directly aligned with erythromycin procurement. The recent records include a completed piggyback award through the Illinois Department of Public Health for Doxycycline Hyclate and Ciprofloxacin Hydrochloride (different antibiotics), and a Seminole County, Florida IFB for Naloxone and drug deactivation systems (opioid-reversal and harm-reduction products unrelated to erythromycin). State and local procurement under this code, when it occurs, centers on antibiotic supply through cooperative purchasing consortia and direct buys by health departments and county public health agencies, typically for emergency preparedness stockpiles, community health initiatives, and ongoing clinical inventory.

The issuing bodies active in this space include state health departments and county health or emergency-management agencies. The Illinois Department of Public Health used the MMCAP Infuse cooperative purchasing vehicle to award a $2,999,999.11 contract to Chartwell Rx LLC on August 28, 2026 for a 12-month initial term with two renewal options. Seminole County's 2023 IFB (posted June 30, 2026, though the due date appears anomalous) sought 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries, requiring electronic bid submission and compliance with E-Verify, drug-free workplace certification, and federal audit provisions. Activity appears concentrated in the Southeast and Midwest, though the recent records do not directly reflect erythromycin-specific opportunities — the code shows limited current procurement momentum aligned with its product scope.